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Purpose: Adiposity has been thought to be related to colorectal carcinogenesis. The aim of 
this study was to explore any association between obesity factors and the presence of colorectal 
adenoma, a potential precancerous lesion.
Patients and methods: Two hundred and six consecutive patients undergoing colonoscopy 
without colorectal cancer were enrolled in the study. Anthropometric measures and other 
adiposity-related laboratory variables including insulin resistance and serum adiponectin levels 
were recorded and correlated with the presence of adenoma.
Results: Colorectal adenoma was detected in 68/206 patients (33%), tubular adenoma(s) in 38 
patients, and tubulovillous or villous in 30 patients. Τwenty-one patients (10.2%) had at least 
one proximal polyp. The size of the largest adenoma was #10 mm in 40 patients and .10 mm 
in 28 patients. No statistically significant difference was observed in body mass index, waist 
circumference, fasting plasma glucose concentration, insulin, homeostatic metabolic assess-
ment, cholesterol, low-density lipoproteins, high-density lipoprotein, or triglycerides between 
patients with and without adenoma. In addition, there was no difference in plasma adiponectin 
between patients with adenoma (11.1 ± 6 µg/mL) and controls (10.2 ± 7.8 µg/mL). Furthermore, 
no significant difference in any parameter was found between patients with advanced adenoma 
and no advanced adenoma, nor between patients with proximal or distal tumors.
Conclusion: This study found that the presence of colorectal adenoma is not correlated with 
any adiposity factor. Moreover, obesity does not appear to be associated with the site or the 
presence of more advanced lesions.
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Introduction
Obesity has been associated with increased risk not only for cardiovascular disease, 
diabetes, and hypertension, but also for malignant disease in various organs.1 A posi-
tive association has been reported between adiposity, particularly central adiposity, 
and colon cancer.1–3 As obesity influences insulin status, it is hypothesized that colon 
neoplasia is through insulin resistance and insulin-like growth factors.4
Considering that colorectal adenomatous polyps are recognized as precancerous 
lesions, a possible association with obesity has been explored in previous studies with 
controversial results. Adiposity and/or central adiposity parameters have been associ-
ated with increased risk of adenoma in some studies5–8 but not in others.9–11 Given that 
adenomatous polyps are common, but only a minority progress to high dysplasia and 
cancer, the role of adiposity in this process is also unknown.
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In recent years adipose tissue has been increasingly 
viewed not only as a storage organ but also as an active 
organ that produces a variety of proteins with various actions. 
Adipocytokines – adipose tissue-derived proteins – including 
leptin, tumor necrosis factor alpha, resistin, and adiponectin, 
have an active role in energy homeostasis and have been 
linked to many aspects of the metabolic syndrome in many 
recent human and animal studies.12–16 Increasing evidence 
suggests that adiponectin plays an important role in the 
pathophysiology of the metabolic syndrome and that its levels 
correlate inversely with body mass index (BMI), plasma tri-
glyceride levels and fasting insulin concentration.12–15 Recent 
data have also revealed that adiponectin probably interferes 
with immunity and carcinogenesis.16–19
The aim of this study was to explore any association 
between obesity factors, including serum adiponectin levels 
and the presence of colorectal adenoma, as well as the site 
and presence of advanced lesion in a large number of patients 
undergoing colonoscopy.
Patients and methods
All patients included in this study underwent colonoscopy in 
the authors’ department between May 2010 and December 
2010. Colonoscopy was performed by two experienced gastro-
enterologists during a voluntary health check-up or for other 
indications – mainly because of occult or overt fecal blood loss 
or a change in bowel movement habits. Bowel preparations 
were carried out using 4 L of polyethylene glycol solution 
(Klean-Prep, Kite Hellas, Athens, Greece). Patients with 
polyps underwent polypectomy and a histological examina-
tion for each polyp was obtained. Among multiple polyps the 
highest dysplasia was considered. A polyp was categorized as 
proximal when localized in cecum, ascending and transverse 
colon, and distal in descending, sigmoid colon and rectum. 
Advanced adenoma was defined as an adenoma more than 
10 mm in diameter and/or with high-grade dysplasia and/or 
containing villous component (at least 25% villous).
Patients with invasive colorectal cancer detected dur-
ing colonoscopy and patients with previous colectomy or 
polypectomy were excluded from the analysis. Patients with 
other malignancies or active systematic disease, as well as 
those under dietary or drug treatment for diabetes mellitus, 
were also excluded.
Anthropometric data, including body weight, height, 
body mass index (BMI) and waist circumference, were 
recorded.
Venous blood samples were collected after an over-
night fast to determine the serum levels of glucose, insulin, 
C-peptide, cholesterol, triglyceride, high-density lipopro-
tein (HDL), and low-density lipoprotein (LDL). Insulin 
resistance was calculated by the homeostatic metabolic 
assessment – insulin resistance (HOMA-IR) method as fol-
lows: HOMA-IR = fasting plasma insulin × fasting plasma 
glucose/405, whereas insulin is expressed in microunits/mL 
and glucose in mg/d.
Venous blood for the assessment of plasma concentration 
of adiponectin was drawn from all subjects after overnight 
fasting. Serum adiponectin levels were measured with 
radioimmunoassay (Human Adiponectin RIA Kit; Linco® 
Research, Inc, St Charles, MO).
This study protocol was approved by the University 
Faculty of Medicine Ethical Committee. Written, informed 
consent was obtained in advance from all subjects.
Differences of age, gender, fasting glucose, insulin 
concentration, HOMA-IR, BMI, waist circumference, and 
plasma adiponectin levels between patients with adenoma 
and controls were assessed. Continuous variables were 
expressed as mean ± standard deviation and were com-
pared using Student’s t-test. Categorical variables were 
expressed as percentages and differences between groups 
were tested for significance by using the chi-square test. All 
analyses were conducted by using statistical software (SPSS 
v 16.0; IBM Corp, Armonk, NY).
Results
Two hundred and six consecutive patients, 119 males and 87 
females, with a mean age of 64.7 ± 10.5 years, were enrolled 
in the study. Colorectal adenoma was detected in 68 patients 
(33%). The histology was that of tubular adenoma in 38 
patients and tubulovillous or villous in 30 patients.
Twenty-one patients (10.2%) had at least one proximal 
polyp, 41 patients had one polyp, while in 27, two or more 
adenomas were detected. The size of the largest adenoma 
was #10 mm in 40 patients and .10 mm in 28 patients, as 
can be seen in Table 1.
The two groups were comparable. Age was not sig-
nificantly different between the patients with and without 
colorectal adenoma (65.8 ± 11 years vs 64.5 ± 10.1 years). 
Moreover, no difference was observed in gender between the 
patients and the controls (38/68 vs 81/138 males).
No statistically significant difference was observed in 
BMI, waist circumference, fasting plasma glucose concentra-
tion, insulin, HOMA, cholesterol, LDL, HDL, and triglycer-
ides between the two groups. In addition, plasma adiponectin 
was not different: 11.1 ± 6 µg/mL in patients with adenoma, 
10.2 ± 7.8 µg/mL in controls (P = 0.41).
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In addition, no significant difference in any parameter 
was found between patients with advanced adenoma and no 
advanced adenoma (Table 1). Furthermore, no statistically 
significant difference was observed in any parameter between 
patients with proximal or distal adenomas (Table 2).
Discussion
Adiposity has been correlated with colon cancer in previous 
studies. Τhe association was strong for men but only weak for 
women.3 In another study, only central adiposity and no other 
body size measures were associated with colorectal cancer 
risk.2 In recent years an inverse correlation has been shown 
to exist between serum adiponectin levels and presence of 
colorectal carcinoma.20–22 It is not known whether the lower 
adiponectin levels result from weight changes and deranged 
metabolism or if adiponectin has a causative role per se. The 
mechanisms of possible adiponectin action have not yet been 
elucidated, but a variety of mechanisms has been postulated. 
Adiponectin might prevent carcinogenesis by inhibition of 
neovascularisation through antiangiogenetic mechanisms, 
suppression of tumor growth, and induction of apoptosis in 
various types of cancers.23,24
As the majority of colorectal cancers derive from ade-
nomas, a possible association might be due either to increased 
risk of adenoma formation in obese patients or to increased 
probability of progression of adenomas in these patients.
In this study, no association was found between adiposity 
factors and the presence of colorectal adenomas in patients. 
Moreover, serum adiponectin levels were not different 
between patients with adenoma and controls. No correla-
tion was found between any adiposity factor and the site of 
adenoma (proximal vs distal). In previous studies, adiposity 
as well as serum adiponectin levels have been correlated 
with the presence of adenoma. Fukumoto et al observed in 
patients with adenomatous polyps slightly lower serum adi-
ponectin than in controls.25 A positive association between 
a variety of adiposity factors and adenomas has also been 
observed by other researchers.26–29 However, no association 
was found in other studies.21,30 The former studies were 
Table 1 Characteristics of participants without adenoma versus those with no advanced and advanced adenoma
Patients without adenoma  
(N = 138)
No advanced adenoma  
(N = 22)
Patients with advanced adenoma   
(N = 46)
Age (years) 63.5 ± 10.1 65.1 ± 12.0 66.2 ± 10.7
Male/female 81/57 12/10 26/20
Smoker (%) 42 (30.4) 7 (31.8) 12 (26.1)
Drinker* (%) 34 (24.6) 5 (22.7) 13 (28.3)
Body weight (kg) 76.7 ± 13.7 73.2 ± 9.1 75.6 ± 14.1
Waist circumference (cm) 99.9 ± 10.9 99.3 ± 8.4 99.2 ± 12.2
BMI (kg/m2) 27.4 ± 4.7 26.4 ± 3.1 27.1 ± 4.2
Glucose (mg/dL) 100.4 ± 26.7 96.2 ± 12.3 102.6 ± 20.5
Cholesterol (mg/dL) 197.8 ± 41 204.2 ± 46.8 201.5 ± 46
LDL (mg/dL) 116.3 ± 32.9 120.5 ± 38.9 112.7 ± 39.5
HDL (mg/dL) 52.2 ± 14.3 52.7 ± 11.9 53.2 ± 16.5
Triglycerides (mg/dL) 138.8 ± 52.1 146.4 ± 54.2 122.9 ± 54.1
Insulin (µU/dL) 5.9 ± 3.6 5.8 ± 4.6 7.1 ± 5.4
C-peptide (ng/mL) 2.4 ± 1.1 2.5 ± 1.7 2.8 ± 1.3
HOMA 1.1 ± 0.7 1.0 ± 0.6 1.3 ± 1.3
Adiponectin (µg/mL) 10.2 ± 7.8 10.9 ± 5.6 11.2 ± 6.3
Note: *Drinker was defined as drinking more than one drink per day.
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; HOMA, homeostatic metabolic assessment; LDL, low-density lipoprotein.
Table  2  Characteristics  of  participants  with  proximal  versus 
distal adenoma
  With proximal  
adenoma (N = 21)
With distal  
adenoma (N = 47)
Age (years) 65.1 ± 11.4 66.6 ± 10.8
Male/Female 9/13 22/24
Body weight (kg) 74.1 ± 10.1 74.4 ± 13.8
Waist  
circumference (cm)
98.7 ± 11.5 99.1 ± 11.6
BMI (kg/m2) 26.4 ± 3.3 27.1 ± 4.1
Glucose (mg/dL) 98.6 ± 18.6 102.1 ± 18.2
Cholesterol (mg/dL) 207.4 ± 62.6 204.4 ± 45.1
LDL (mg/dL) 128.4 ± 46.2 111.3 ± 40.6
HDL (mg/dL) 50.2 ± 17.2 53.3 ± 14.5
Triglycerides (mg/dL) 148.2 ± 65 124.7 ± 54.7
Insulin (µU/mL) 6.3 ± 3.6 6.9 ± 6.3
C-peptide (ng/mL) 2.9 ± 1.7 2.7 ± 1.3
HOMA 0.9 ± 0.5 1.3 ± 1.2
Adiponectin (µg/mL) 11.7 ± 8.3 10.8 ± 5.0
Abbreviations:  BMI,  body  mass  index;  HDL,  high-density  lipoprotein;  HOMA, 
homeostatic metabolic assessment; LDL, low-density lipoprotein.
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mainly from Japan and Korea whereas the latter were from 
Western countries. Patients from the Far East were younger 
(mean age 48–58 vs 56–63 years) and with lower BMI (mean 
BMI 22.8–23.7 vs 25.8–27) compared with patients from the 
West. Probably other factors, for example, diet, play a role in 
colorectal cancer carcinogenesis and not adiposity per se. In 
an experimental study, Fujisawa et al observed a significant 
increase in cell proliferative activity in the colonic epithelium 
of adiponectin-deficient mice when compared with wild-
type mice fed a high-fat diet; however, no difference was 
observed between wild-type and adiponectin-deficient mice 
fed a basal diet.31 Also, genetic factors may contribute to the 
development and/or progression of a colorectal adenoma 
and the prevalence of these factors varies among different 
populations.
In a previous study, Sedjo et al found that weight gain 
was more strongly associated with the risk of colorectal 
adenoma than adiposity parameters at times more distant 
from the time of colonoscopy.32 Moreover, no association was 
found between serum adiponectin and adenoma recurrence 
in a prospective study where a large number of patients were 
followed up over a 4-year period.33 In contrast, recurrence 
was correlated with serum homocysteine concentrations 
and a diet high in fat and low in fiber.33 These studies point 
out the role of current diet and body weight changes in the 
development and progression of colorectal tumors.
It is known that only a percentage of colorectal adenomas 
progress to advanced lesions and a very small percentage to 
cancer and this process takes several years, usually one to 
two decades. This study divided patients with adenomatous 
polyps into two groups: (1) those with severe dysplasia and/
or villous component and (2) those without. No difference 
was found between patients with advanced adenoma and 
those with nonadvanced adenoma.
Similar results were found in a study by Kumor et al, 
where no difference in the level of adipokines in serum was 
observed between patients with high-grade and low-grade 
dysplastic polyps.30 Also, Nakajima et al did not find any   
correlation between adiponectin and size of adenoma.26 
However, positive association has been found between 
adiposity and presence of advanced tumors in other studies, 
where patients with advanced lesions presented even lower 
serum levels of adiponectin.26,28 In some studies, adiponectin 
levels were even lower in patients with colorectal cancer than 
patients with adenoma.21,29,30 Decreased serum adiponectin 
is probably not involved in the development of colorectal 
cancer but results secondary to the derangements that occur 
during the development and progression of colon   cancer. 
This has not been studied in patients with colorectal 
cancer, but Ishikawa et al observed that serum adiponectin 
concentration was inversely correlated with tumor size 
and Tumor-Nodes-Metastasis Classification of Malignant 
Tumours stage in patients with gastric cancer.34
In conclusion, this study found that presence of colorectal 
adenoma is not correlated with any adiposity factor.   However, 
further prospective studies on large patient populations from 
various countries with different diets and habits are needed 
to detect possible minor differences in any parameter and 
their association with colorectal adenoma.
Disclosure
The authors declare no conflicts of interest in this work.
References
  1.  Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and 
insulin, body size, and indent colorectal cancer. J Natl Cancer Inst. 
1999;91(13):1147–1154.
  2.  MacInnis RJ, English DR, Haydon AM, Hopper JL, Gertig DM, Giles GG. 
Body size and composition and risk of rectal cancer   (Australia). Cancer 
Causes Control. 2006;17(10):1291–1297.
  3.  Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon 
and rectal cancer in the European Prospective Investigation Into Cancer 
and Nutrition (EPIC). J Natl Cancer Inst. 2006;98(13):920–931.
  4.  Tsugane S, Inoue M. Insulin resistance and cancer: epidemiological 
evidence. Cancer Sci. 2010;101(5):1073–1079.
  5.  Johnson KT, Harmsen WS, Limburg PJ, Carston MJ, Johnson CD. Visceral 
fat analysis at CT colonography. Acad Radiol. 2006;13(8):963–938.
  6.  Kang HW, Kim D, Kim HJ, et al. Visceral obesity and insulin resistance 
as risk factors for colorectal adenoma: a cross-sectional, case-control 
study. Am J Gastroenterol. 2010;105(1):178–187.
  7.  Morimoto LM, Newcomb PA, Ulrich CM, Bostick RM, Lais CJ, 
Potter JD. Risk factors for hyperplastic and adenomatous polyps: 
evidence for malignant potential? Cancer Epidemiol Biomarkers Prev. 
2002;11(10 Pt 1):1012–1018.
  8.  Terry MB, Neugut AI, Bostick RM, et al. Risk factors for advanced 
colorectal adenomas: a pooled analysis. Cancer Epidemiol Biomarkers 
Prev. 2002;11(7):622–629.
  9.  Lieberman DA, Prindiville S, Weiss DG, Willett W; VA   Cooperative 
Study Group 380. Risk factors for advanced colonic neoplasia and 
hyperplastic polyps in asymptomatic individuals. JAMA. 2003;290(22): 
2959–2967.
  10.  Bayerdörffer E, Mannes GA, Ochsenkühn T, Köpcke W, Wiebecke B, 
Paumgartner G. Increased risk of ‘high-risk’ colorectal adenomas in 
overweight men. Gastroenterology. 1993;104(1):137–144.
  11.  Stemmermann GN, Heilbrun LK, Nomura AM. Association of diet and 
other factors with adenomatous polyps of the large bowel: a prospective 
autopsy study. Am J Clin Nutr. 1988;47(2):312–317.
  12.  Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, 
adipose-specific protein, adiponectin, in type 2 diabetic patients. 
  Arterioscler Thromb Vasc Biol. 2000;20(6):1595–1599.
  13.  Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadi-
ponectinemia with coronary artery disease in men. Arterioscler Thromb 
Vasc Biol. 2003;23(1):85–89.
  14.  Kondo H, Shimomura I, Matsukawa Y, et al. Association of adiponectin 
mutation with type 2 diabetes: a candidate gene for the insulin resistance 
syndrome. Diabetes. 2002;51(7):2325–2328.
  15.  Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived 
plasma protein, inhibits endothelial NF-κB signalling through a cAMP-
dependent pathway. Circulation. 2000;102(11):1296–1301.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
260
Chronis et alClinical and Experimental Gastroenterology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-and-experimental-gastroenterology-journal
Clinical and Experimental Gastroenterology is an international, peer-
reviewed, open access journal, publishing all aspects of gastroenterology 
in the clinic and laboratory, including: Pathology, pathophysiology 
of gastrointestinal disease; Investigation and treatment of gastointes-
tinal disease; Pharmacology of drugs used in the alimentary tract; 
Immunology/genetics/genomics related to gastrointestinal disease.   
This journal is indexed on CAS. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system. Visit http://www.dovepress.com/testimonials.php to read real 
quotes from published authors.
Clinical and Experimental Gastroenterology 2011:4
  16.  Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of 
C-reactive protein with adiponectin in blood stream and adipose tissue. 
Circulation. 2003;107(5):671–674.
  17.  Engeli S, Feldpausch M, Gorzelniak K, et al. Association between 
adiponectin and mediators of inflammation in obese women. Diabetes. 
2003;52(4):942–947.
  18.  Petridou E, Mantzoros C, Dessypris N, et al. Plasma adiponectin con-
centrations in relation to endometrial cancer: a case-control study in 
Greece. J Clin Endocrinol Metab. 2003;88(3):993–997.
  19.  Miyoshi Y, Funahashi T, Kihara S, et al. Association of serum adi-
ponectin levels with breast cancer risk. Clin Cancer Res. 2003;9(15): 
5699–5704.
  20.  Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low 
plasma adiponectin levels and risk of colorectal cancer in men: a pro-
spective study. J Natl Cancer Inst. 2005;97(22):1688–1694.
  21.  Erarslan E, Turkay C, Koktener A, Koca C, Uz B, Bavbek N. 
  Association of visceral fat accumulation and adiponectin levels with 
colorectal neoplasia. Dig Dis Sci. 2009;54(4):862–868.
  22.  Gonullu G, Kahraman H, Bedir A, Bektas A, Yücel I. Association 
between adiponectin, resistin, insulin resistance, and colorectal tumors. 
Int J Colorectal Dis. 2010;25(2):205–212.
  23.  Bråkenhielm E, Veitonmäki N, Cao R, et al. Adiponectin-induced antian-
giogenesis and antitumor activity involve caspase-mediated endothelial 
cell apoptosis. Proc Natl Acad Sci U S A. 2004;101(8):2476–2481.
  24.  Michalakis K, Williams CJ, Mitsiades N, et al. Serum adiponectin con-
centrations and tissue expression of adiponectin receptors are reduced 
in patients with prostate cancer: a case control study. Cancer Epidemiol 
Biomarkers Prev. 2007;16(2):308–313.
  25.  Fukumoto J, Otake T, Tajima O, et al. Adiponectin and colorectal 
adenomas: Self Defense Forces Health Study. Cancer Sci. 2008;99(4): 
781–786.
  26.  Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokines as new 
promising markers of colorectal tumors: adiponectin for colorectal 
adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci. 
2010;101(5):1286–1291.
  27.  Yamaji T, Iwasaki M, Sasazuki S, Tsugane S. Interaction between adi-
ponectin and leptin influences the risk of colorectal adenoma. Cancer 
Res. 2010;70(13):5430–5437.
  28.  Otake S, Takeda H, Suzuki Y, et al. Association of visceral fat 
accumulation and plasma adiponectin with colorectal adenoma: 
evidence for participation of insulin resistance. Clin Cancer Res. 
2005;11(10):3642–3646.
  29.  Otake S, Takeda H, Fujishima S, et al. Decreased levels of plasma 
adiponectin associated with increased risk of colorectal cancer. World 
J Gastroenterol. 2010;16(10):1252–1257.
  30.  Kumor A, Daniel P, Pietruczuk M, Małecka-Panas E. Serum   leptin, 
adiponectin, and resistin concentration in colorectal adenoma 
and carcinoma (CC) patients. Int J Colorectal Dis. 2009;24(3): 
275–281.
  31.  Fujisawa T, Endo H, Tomimoto A, et al. Adiponectin suppresses 
colorectal carcinogenesis under the high-fat diet condition. Gut. 2008; 
57(11):1531–1538.
  32.  Sedjo RL, Byers T, Levin TR, et al. Change in body size and the risk 
of colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 2007; 
16(3):526–531.
  33.  Bobe G, Murphy G, Rogers CJ, et al. Serum adiponectin, leptin, 
C-peptide, homocysteine, and colorectal adenoma recurrence in the 
Polyp Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2010; 
19(6):1441–1452.
  34.  Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, 
Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res. 
2005;11(2 Pt 1):466–472.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
261
Adiposity factors are not related to colorectal adenomas